Allt inom IR
Nanexa publishes interim report for January-March 2026
Opened the year with strong preclinical results for once-monthly and quarterly dosing of semaglutide
Nanexa resolves on set-off of outstanding loan
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, CANADA, HONG KONG, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION, OR DISTRIBUTION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. FURTHER RESTRICTIONS APPLY.